SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Incyte (INCY)
An SI Board Since January 1996
Posts SubjectMarks Bans Symbol
3202 131 0 INCY
Emcee:  scaram(o)uche Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
2652>So what is the reason for the apparent differential activity? < As a bitformer_pgs-5/4/2011
2651<Some feel the better affect on anemia from the YMI drug is important. What dBiotech Jim-5/4/2011
2650pcrutch isn't taking my bait ;-) But if we assume (despite the perils) thatformer_pgs15/3/2011
2649Transcript: seekingalpha.com Some feel the better affect on anemia from the YMtuck-5/3/2011
2648Real damn close to a 10 year high.sjemmeri-5/3/2011
26475/3/11 cc notes 1. Opening remarks ( by Rich Levy) Rux NDA and MAA in June; NDsoftware salesperson25/3/2011
2646Rather pleasant milestone. :-)scaram(o)uche-5/3/2011
2645PFE reports news for tofacitinib in RA based on ORAL Standard and ORAL Step Ph3 Biotech Jim-4/28/2011
2644Thanks, BJ for the valuable feedback. I agree that PFE's pan-Jak has a diffequantman-4/22/2011
2643Hey Q-man- I am traveling and in DC and my hotel connection does not allow meBiotech Jim14/21/2011
2642<i>Pfizer commented</i>......... Just after 2 Rigel made a u-turn? Steve Lokness-4/21/2011
2641Some further info on PFE's Tofacetinib for consideration: ------------------quantman-4/21/2011
2640This is the link for the abstract posted today at the London RA conference on PFquantman-4/21/2011
2639Data reported by INCY competitor YM Biosciences on its JAK1/JAK2 inhibitor this Biotech Jim-4/18/2011
2638PFE releases top line data on tofacitinib in RA. The PR only states the ACR20 dBiotech Jim-4/15/2011
2637Per the YMB, INCY has been upgraded by UBS.tom pope-4/8/2011
2636INCY receives $15 M milestone from NVS for C-met inhibitor program... investor.Biotech Jim-4/5/2011
2635Parking this abstract on a competitor's JAK1/JAK2 inhibitor. In the recent Biotech Jim-3/30/2011
2634My broker sent me a bunch of analyst reports on INCY today. (Full service brokeA.J. Mullen-3/29/2011
2633The pipeline is impressive, but I'm starting to worry about the cash necessaA.J. Mullen-3/28/2011
2632Incyte's Ruxolitinib (INCB18424) Meets Primary Endpoint in Second Phase III Biotech Jim-3/15/2011
2631And in ORAL Sync primary endpoints met: siliconinvestor.com Mildly positive retuck-3/4/2011
2630Recent ownership reports SC 13G/A INCYTE CORP filed this Form SCtnsaf-2/10/2011
26292/10/11 cc notes 1. Opening remarks Launch 18424( ruxolitinib) late ’11 - - 6software salesperson12/10/2011
2628INCYTE CORP filed this Form SC 13G/A on February 04, 2011 BlackRock Inc. 40 Eastnsaf-2/4/2011
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News